4DMT completed enrollment in its Phase 3 trial for 4D-150 within approximately 11 months, ahead of initial projections, reflecting strong interest from both investigators and patients. Topline data from this trial is anticipated in the first half of 2027. Additionally, the company expects to release two-year data from its PRISM wet AMD Phase 2b trial in mid-2026 and from the SPECTRA diabetic macular edema (DME) trial in the second half of 2026.
The company’s cash position remains robust, with $514 million in cash, cash equivalents, and marketable securities, which is projected to fund operations into the second half of 2028. This strong financial backing positions 4DMT well for its ongoing and upcoming clinical trials, including the initiation of the global Phase 3 trial for 4D-150 in DME expected in Q3 2026.
4DMT's leadership has also seen changes aimed at supporting its late-stage execution and commercial readiness, including the appointment of Kristian Humer as Chief Financial Officer and the expansion of its board with Glenn P. Sblendorio. These strategic moves are expected to enhance the company's operational execution and governance controls as it advances its innovative therapies.
Overall, 2025 was a transformative year for 4DMT, marked by meaningful progress in clinical trials, a strengthened financial position, and strategic partnerships that are expected to drive future growth and success in the biotechnology sector.
